Inventor · disambiguated record
Boopathy Ramakrishnan
Also filed as: RAMAKRISHNAN BOOPATHY
27 granted patents·23 pending applications·42 citations·filing 2004–2025
94Inventor score
Files withVISTERRA INC40QASBA PRADMAN K3US HEALTH2US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH & HUMAN SERVIC2GOVT OF THE US AS REPRESENTED1
Top patents by PatentIndex Score
50 records- 0197US11136385B2Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody moleculeVISTERRA INC·Filed 2020·Granted Oct 5, 2021·4 cites·38 claims
- 0297US10954296B2Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGAVISTERRA INC·Filed 2020·Granted Mar 23, 2021·4 cites·51 claims
- 0396US10968270B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 6, 2021·3 cites·30 claims
- 0493US10385123B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2018·Granted Aug 20, 2019·8 cites·30 claims
- 0592US9738726B2HER2-specific monoclonal antibodies and conjugates thereofUS HEALTH·Filed 2014·Granted Aug 22, 2017·12 cites·32 claims
- 0691US2025066464A1Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2024·Application pending·0 cites
- 0789US11912781B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2022·Granted Feb 27, 2024·1 cites·10 claims
- 0887US10981982B2Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 20, 2021·1 cites·48 claims
- 0986US12297249B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Granted May 13, 2025·0 cites·13 claims
- 1086US12264203B2Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Apr 1, 2025·0 cites·13 claims
- 1184US12227587B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Feb 18, 2025·0 cites·10 claims
- 1283US12415865B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Sep 16, 2025·0 cites·2 claims
- 1383US12187807B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Jan 7, 2025·0 cites·4 claims
- 1483US11168131B2Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2016·Granted Nov 9, 2021·4 cites·15 claims
- 1581US2025059249A1Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 1680US12091451B2Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2021·Granted Sep 17, 2024·0 cites·18 claims
- 1776US11945868B2Antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2018·Granted Apr 2, 2024·1 cites·37 claims
- 1876US7482133B2Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their useUS HEALTH·Filed 2005·Granted Jan 27, 2009·2 cites·7 claims
- 1976US2025296982A1Engineered polypeptides and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 2074US2025043014A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2173US2024301065A1Antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2271US12084484B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2020·Granted Sep 10, 2024·0 cites·23 claims
- 2371US11773179B2Antibody molecules to C5aR1 and uses thereofVISTERRA INC·Filed 2021·Granted Oct 3, 2023·0 cites·4 claims
- 2471US8512991B2Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of useQASBA PRADMAN K·Filed 2007·Granted Aug 20, 2013·2 cites·7 claims
- 2571US2025171555A1Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 2671US2024342300A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2770US2024092921A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2023·Application pending·0 cites
- 2870US2019330326A1Antibody molecules to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2019·Application pending·0 cites
- 2970US2024376173A1Methods of using interleukin-2 agentsVISTERRA INC·Filed 2024·Application pending·0 cites
- 3067US2025382379A1Humanized antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3166US12098178B2Methods of using interleukin-2 agentsVISTERRA INC·Filed 2021·Granted Sep 24, 2024·0 cites·31 claims
- 3264US12338291B2Humanized antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2020·Granted Jun 24, 2025·0 cites·21 claims
- 3364US2022267418A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2021·Application pending·0 cites
- 3463US2017145086A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2016·Application pending·0 cites
- 3561US11858980B2Engineered polypeptides and uses thereofVISTERRA INC·Filed 2017·Granted Jan 2, 2024·0 cites·22 claims
- 3661US2020277358A1Engineered polypeptides and uses thereofVISTERRA INC·Filed 2020·Application pending·0 cites
- 3760US11969476B2Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2021·Granted Apr 30, 2024·0 cites·27 claims
- 3860US2022226442A1Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2022·Application pending·0 cites
- 3959US2023348614A1Engineered antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2022·Application pending·0 cites
- 4058US2009233345A1Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their useGOVT OF THE US AS REPRESENTED·Filed 2009·Application pending·0 cites
- 4154US2023257449A1Compositions and methods for treating and preventing influenzaVISTERRA INC·Filed 2020·Application pending·0 cites
- 4254US2007258986A1Targeted Delivery System for Bioactive AgentsGOVT OF THE US AS RESPRESENTED·Filed 2004·Application pending·0 cites
- 4353US2022059184A1Methods for identifying epitopes and paratopesVISTERRA INC·Filed 2019·Application pending·0 cites
- 4453US2021340266A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2021·Application pending·0 cites
- 4551US9222080B2Alpha 1-3 N-galactosylstransferase with altered donor specificities, compositions and methods of useQASBA PRADMAN K·Filed 2013·Granted Dec 29, 2015·0 cites·9 claims
- 4651US8425901B2Alpha 1-3 N-galactosyltransferase with altered donor specificitiesQASBA PRADMAN K·Filed 2007·Granted Apr 23, 2013·0 cites·16 claims
- 4750US2014178985A1Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of useUS OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH & HUMAN SERVIC·Filed 2013·Application pending·0 cites
- 4848US11890319B2Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2018·Granted Feb 6, 2024·0 cites·23 claims
- 4944US8703459B2Catalytic domains of beta(1,4)-galactosyltransferase I having altered metal ion specificityQASBA PRADMAN·Filed 2004·Granted Apr 22, 2014·0 cites·12 claims
- 5043US2015018522A1Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificityUS OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH & HUMAN SERVIC·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Boopathy Ramakrishnan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →